McConnell Elizabeth J, McLemore Elisabeth C, Talac Robert, Joshi Lokesh, Nelson Heidi
Arizona State University, Arizona Biodesign Institute, Tempe, Arizona, USA.
J Surg Res. 2004 Nov;122(1):103-12. doi: 10.1016/j.jss.2004.06.017.
Activation of Vbeta8+ T cells with superantigen staphylococcal enterotoxin B (SEB) and use of an antitumor, anti-CD3 bispecific antibody (BsAb) leads to tumor protective immunity. We hypothesize that Vbeta8+ T-cell activation in combination with BsAb is crucial for tumor protective immunity in this model.
Adolescent C3H/HeN mice were intravenously injected with syngeneic CL62 melanoma to establish pulmonary metastasis. Three days after establishing pulmonary metastasis, predominantly Vbeta8+ T cells are activated with 50 mug of intraperitoneal superantigen SEB. T cells were depleted at different time points in relation to SEB administration to assess the effect on protective immunity against a second tumor challenge.
Protective immunity is significantly (P < 0.008) decreased when Vbeta8+ depletion occurs 6 h after SEB injection, as growth of rechallenged CL62 melanoma occurred in 43%. Protective immunity is present at all other time points when mice survive Vbeta8+ T-cell depletion. Survival of animals treated with SEB/BsAb (82%) is significantly better (P < 0.002) than with SEB alone (60%) or nontreated control (0%). Survival when Vbeta8+ T-cell depletion occurred at 6 h and 48 h post-SEB is 72% and 77%, respectfully, and is statistically indistinguishable (P < 0.232 and P < 0.602). If T-cell depletion was conducted before SEB administration, however, the combination of SEB and BsAb did not result in significant protective immunity. T-cell depletion before the use of SEB alone, without BsAb, failed to result in significant protective immunity.
Depletion of Vbeta8+ T cells 6 h after activation disrupts the development of protective immunity.
用超抗原葡萄球菌肠毒素B(SEB)激活Vβ8 + T细胞并使用抗肿瘤抗CD3双特异性抗体(BsAb)可产生肿瘤保护性免疫。我们假设在该模型中,Vβ8 + T细胞激活与BsAb联合对于肿瘤保护性免疫至关重要。
给青春期C3H/HeN小鼠静脉注射同基因CL62黑色素瘤以建立肺转移模型。在建立肺转移模型三天后,用50μg腹腔注射超抗原SEB激活主要的Vβ8 + T细胞。在与SEB给药相关的不同时间点清除T细胞,以评估对第二次肿瘤攻击的保护性免疫的影响。
当在SEB注射后6小时进行Vβ8 + T细胞清除时,保护性免疫显著降低(P < 0.008),因为再次攻击的CL62黑色素瘤有43%生长。当小鼠在Vβ8 + T细胞清除后存活时,在所有其他时间点均存在保护性免疫。用SEB/BsAb治疗的动物存活率(82%)显著高于单独使用SEB(60%)或未治疗的对照组(0%)(P < 0.002)。在SEB后6小时和48小时进行Vβ8 + T细胞清除时的存活率分别为72%和77%,在统计学上无显著差异(P < 0.232和P < 0.602)。然而,如果在SEB给药前进行T细胞清除,则SEB和BsAb的联合使用不会产生显著的保护性免疫。在单独使用SEB(不使用BsAb)之前进行T细胞清除也未能产生显著的保护性免疫。
激活后6小时清除Vβ8 + T细胞会破坏保护性免疫的发展。